ArticleWorld journal of gastrointestinal oncology2026
Computed tomography with carcinoembryonic antigen and carbohydrate antigen 19-9 in diagnosing lymph node metastasis of early gastric cancer.
Article in World journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is the fifth most prevalent and fourth most lethal malignancy globally. China bears a disproportionately high burden, accounting for 44.0% of new cases and 48.6% of deaths worldwide. In early GC (EGC), the presence of lymph node metastasis (LNM) is a critical prognostic determinant that directly guides therapeutic strategy. While multi-detector computed tomography (CT) and serum biomarkers carcinoembryonic antigen (CEA)/carbohydrate antigen 19-9 (CA19-9) are established diagnostic tools, each demonstrates limited efficacy when used independently. This study therefore aims to verify whether a combined diagnostic approach integrating multi-detector CT (MDCT) with serum CEA/CA19-9 can significantly improve the accuracy of LNM detection in EGC patients.
aimTo investigate the diagnostic value of CT combined with CEA or CA19-9 for detecting LNM in EGC.
methodsThis retrospective study included 120 patients with EGC confirmed by gastroscopic biopsy at our institution (Huai'an Hospital of Huai'an City) between February 2024 and August 2024. Based on postoperative pathological findings, participants were categorized into a LNM group (
resultsSerum analysis showed significantly elevated CEA and CA19-9 levels and higher positivity rates in the metastasis group (
conclusionThe combination of CT with CEA or CA19-9 improves sensitivity for detecting LNM in EGC, supporting personalized treatment planning and demonstrating clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.